Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with
considerable pathophysiological and clinical variability across patients [1]. For this reason …

The number of pharmacological treatments available for COPD has increased markedly in
the last years, mostly corresponding to new agents, combinations and devices within know …

Guidelines for chronic obstructive pulmonary disease (COPD) management are based
largely on results from double-blind randomised controlled trials (RCTs) of efficacy. These …

Evidence-based guidelines for the pharmacological management of chronic obstructive
pulmonary disease (COPD) were updated in 2020 by a multidisciplinary panel of experts (1) …

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
worldwide. Treatment advances over the last decade, although limited, have precipitated the …

Key characteristics of chronic obstructive pulmonary disease (COPD) that significantly affect
health-related quality of life (HRQoL) include chest symptoms, dyspnea, cough, sputum …

The Global initiative for chronic Obstructive Lung Disease (GOLD) strategy document
provides recommendations for the diagnosis, management and prevention of chronic …

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality
worldwide (1). The revised Global Initiative for Chronic Obstructive Lung Disease (GOLD) …

Clinicians responsible for treating pulmonary disease often encounter challenges in the
management of patients with COPD. This is due in part to the number of drugs now available …

Rationale: Clinical trials in chronic obstructive pulmonary disease (COPD) usually require
evidence of airflow obstruction and clinical risk factors. International Classification of …